Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
ACS Omega|August 19, 2024
Design and Synthesis of Red-Absorbing Fluoran Leuco Dyes Supported by Computational ScreeningVitor Angelo Fonseca Deichmann, Dennis Chercka, David Danner, et al.ANZ Journal of Surgery|March 5, 2004
Pasieka Illness Questionnaire: its value in primary hyperparathyroidismBenedikt Greutelaers, Katrin Kullen, James Kollias, et al.Journal of Clinical Periodontology|January 17, 2024
Periodontal disease prevalence and oral hygiene status of adults with cystic fibrosis: A case-control studyNiamh Coffey, Fiona O'Leary, Francis Burke, et al.Clinical Therapeutics|December 26, 2007
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialAnthony H Barnett, Jude Burger, Don Johns, et al.Journal of Medical Imaging (Bellingham, Wash.)|March 21, 2022
Synchrotron radiation-based phase-contrast microtomography of human dental calculus allows nondestructive analysis of inclusions: implications for archeological samplesRobert C Power, Amanda G Henry, Julian Moosmann, et al.Journal of Clinical Pharmacology|November 25, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White AdultsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.British Dental Journal|April 25, 2025
Caries in a cohort of adults with cystic fibrosis: a cross-sectional studyFiona O Leary, Niamh Coffey, Francis M Burke, et al.Clinical and Translational Science|November 23, 2021
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)Dipti Pawaskar, Xi Chen, Fiona Glassman, et al.Journal of Clinical Pharmacology|September 6, 2025
A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre-Filled Pen Versus Pre-Filled Syringe in Healthy ParticipantsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.Internal Medicine Journal|August 22, 2024
Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional studyGregory R Fulcher, Neale D Cohen, Katherine Davies, et al.Pageof 6